Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
24.55
Dollar change
0.00
Percentage change
0.00
%
Index- P/E- EPS (ttm)-5.15 Insider Own1.19% Shs Outstand42.43M Perf Week-4.14%
Market Cap1.04B Forward P/E- EPS next Y-5.50 Insider Trans-4.36% Shs Float41.93M Perf Month-5.94%
Income-181.29M PEG- EPS next Q-1.25 Inst Own76.14% Short Float6.09% Perf Quarter31.92%
Sales27.07M P/S38.48 EPS this Y-1.53% Inst Trans2.13% Short Ratio7.07 Perf Half Y23.37%
Book/sh8.74 P/B2.81 EPS next Y-6.59% ROA-36.04% Short Interest2.56M Perf Year21.72%
Cash/sh12.41 P/C1.98 EPS next 5Y- ROE-56.50% 52W Range12.54 - 28.91 Perf YTD35.79%
Dividend Est.- P/FCF- EPS past 5Y-12.36% ROI-44.11% 52W High-15.08% Beta0.89
Dividend TTM- Quick Ratio8.08 Sales past 5Y38.55% Gross Margin75.73% 52W Low95.77% ATR (14)1.39
Dividend Ex-Date- Current Ratio8.08 EPS Y/Y TTM-36.03% Oper. Margin-792.74% RSI (14)53.51 Volatility4.91% 6.07%
Employees284 Debt/Eq0.12 Sales Y/Y TTM87.99% Profit Margin-669.66% Recom1.25 Target Price43.20
Option/ShortYes / Yes LT Debt/Eq0.11 EPS Q/Q-14.85% Payout- Rel Volume0.00 Prev Close24.55
Sales Surprise-23.66% EPS Surprise5.95% Sales Q/Q67.58% EarningsFeb 20 BMO Avg Volume361.55K Price24.55
SMA20-1.07% SMA5012.75% SMA20019.19% Trades Volume0 Change0.00%
Date Action Analyst Rating Change Price Target Change
Sep-11-23Upgrade B. Riley Securities Neutral → Buy
Aug-31-22Initiated Cowen Outperform
Jul-28-22Initiated Barclays Overweight $30
Jul-06-22Resumed Canaccord Genuity Buy $60
Apr-13-22Downgrade B. Riley Securities Buy → Neutral $62 → $33
Apr-07-22Resumed Cantor Fitzgerald Overweight $100 → $80
Feb-14-22Initiated Morgan Stanley Equal-Weight $60
Dec-17-21Initiated SVB Leerink Outperform $70
Dec-09-21Initiated Needham Buy $85
Sep-30-21Initiated B. Riley Securities Buy $56
Mar-05-24 04:35PM
Feb-28-24 07:00AM
Feb-20-24 07:05AM
Feb-07-24 07:00AM
Jan-22-24 10:54AM
02:02AM Loading…
Jan-05-24 02:02AM
Dec-14-23 07:00AM
Nov-30-23 07:00AM
Nov-02-23 08:46AM
07:00AM
06:04AM
Oct-30-23 07:00AM
Oct-19-23 07:00AM
04:00AM
Sep-14-23 10:12AM
07:54AM Loading…
Sep-12-23 07:54AM
06:36AM
Sep-11-23 02:19PM
07:00AM
Sep-05-23 07:00AM
Aug-03-23 06:59AM
Jul-18-23 07:00AM
06:45AM
Jul-14-23 06:47AM
Jul-13-23 06:40PM
Jul-12-23 10:23PM
04:01PM
Jun-23-23 07:30AM
Jun-13-23 07:00AM
May-31-23 07:00AM
08:05AM Loading…
May-14-23 08:05AM
May-11-23 06:59AM
May-10-23 08:00AM
07:29AM
May-04-23 09:55AM
07:00AM
06:45AM
Apr-14-23 07:00AM
Apr-03-23 07:00AM
Mar-31-23 06:36AM
Mar-29-23 08:17AM
Mar-28-23 07:00AM
Feb-28-23 09:00AM
07:00AM
Feb-14-23 06:59AM
Feb-08-23 07:00AM
Jan-29-23 09:46AM
Jan-11-23 07:00AM
Jan-04-23 07:00AM
Nov-10-22 09:09AM
Nov-09-22 08:03AM
Nov-08-22 07:00AM
05:03AM
Nov-04-22 07:00AM
Nov-03-22 07:00AM
Oct-10-22 07:00AM
Sep-19-22 04:05PM
Sep-07-22 07:00AM
Sep-06-22 07:00AM
Aug-24-22 07:48PM
Aug-04-22 06:59AM
Aug-02-22 04:05PM
Jul-12-22 04:05PM
07:00AM
Jun-30-22 08:39AM
Jun-08-22 07:00AM
Jun-01-22 07:00AM
May-26-22 05:00PM
May-16-22 07:03AM
May-05-22 06:59AM
Apr-20-22 09:17AM
Apr-11-22 11:57AM
07:44AM
07:41AM
07:00AM
Apr-08-22 04:07PM
03:02PM
01:00PM
Apr-07-22 08:00AM
Apr-06-22 08:00AM
Apr-04-22 11:45AM
Mar-31-22 03:10PM
Mar-22-22 08:30AM
Mar-08-22 04:35PM
07:00AM
Mar-01-22 07:00AM
Feb-09-22 07:00AM
Feb-03-22 05:15AM
Feb-02-22 05:38PM
Jan-20-22 09:38PM
Jan-12-22 09:38AM
Jan-10-22 08:21AM
Jan-05-22 07:00AM
Dec-03-21 11:58AM
Nov-11-21 07:00AM
Nov-09-21 08:00AM
Nov-05-21 07:02AM
Nov-04-21 06:59AM
06:45AM
Nov-02-21 07:10AM
Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lee KevinChief Executive OfficerJan 03 '24Sale17.508,703152,302390,428Jan 04 06:25 PM
Crockett NigelChief Business OfficerJan 03 '24Sale17.502,64346,25248,716Jan 04 06:28 PM
Skynner MichaelChief Technology OfficerJan 03 '24Sale17.502,64346,25295,839Jan 04 06:26 PM
Milnes AlistairChief Operating OfficerJan 03 '24Sale17.502,64346,25273,196Jan 04 06:27 PM
Keen NicholasChief Scientific OfficerJan 03 '24Sale17.502,64046,20063,593Jan 04 06:34 PM
Thompson Travis AlvinChief Accounting OfficerJan 03 '24Sale17.5060410,57023,375Jan 04 06:36 PM
Lee KevinChief Executive OfficerOct 03 '23Sale20.001,47029,400322,131Oct 05 05:46 PM
Crockett NigelChief Business OfficerOct 03 '23Sale20.004428,84029,359Oct 05 05:48 PM
Milnes AlistairChief Operating OfficerOct 03 '23Sale20.004428,84036,839Oct 05 05:47 PM
Skynner MichaelChief Technology OfficerOct 03 '23Sale20.004428,84070,482Oct 05 05:46 PM
Keen NicholasChief Scientific OfficerOct 03 '23Sale20.002725,44038,233Oct 05 05:49 PM
Thompson Travis AlvinChief Accounting OfficerOct 03 '23Sale20.00541,0807,979Oct 05 05:50 PM
Lee KevinChief Executive OfficerJul 03 '23Sale25.101,49837,600323,601Jul 06 04:51 PM
Crockett NigelChief Business OfficerJul 03 '23Sale25.1045111,32029,801Jul 06 04:49 PM
Skynner MichaelChief Technology OfficerJul 03 '23Sale25.1045111,32070,924Jul 06 04:53 PM
Milnes AlistairChief Operating OfficerJul 03 '23Sale25.1045111,32037,281Jul 06 04:52 PM
Keen NicholasChief Scientific OfficerJul 03 '23Sale25.103368,43438,505Jul 06 04:50 PM
Thompson Travis AlvinChief Accounting OfficerJul 03 '23Sale25.10611,5318,033Jul 06 04:57 PM
Lee KevinChief Executive OfficerApr 03 '23Sale21.111,48631,369325,099Apr 05 04:39 PM
Milnes AlistairChief Operating OfficerApr 03 '23Sale21.114479,43637,732Apr 05 04:42 PM
Skynner MichaelChief Technology OfficerApr 03 '23Sale21.114479,43671,375Apr 05 04:43 PM
Crockett NigelChief Business OfficerApr 03 '23Sale21.114479,43630,252Apr 05 04:40 PM
Kalowski LeePresident and CFOApr 03 '23Sale21.113767,93730,309Apr 05 04:41 PM
Keen NicholasChief Scientific OfficerApr 03 '23Sale21.113196,73438,841Apr 05 04:43 PM